|Bid||75.21 x 1300|
|Ask||77.90 x 900|
|Day's Range||75.53 - 76.62|
|52 Week Range||75.53 - 94.26|
|Beta (5Y Monthly)||0.49|
|PE Ratio (TTM)||7.45|
|Forward Dividend & Yield||3.33 (4.37%)|
|Ex-Dividend Date||Mar 08, 2022|
|1y Target Est||102.00|
Subscribe to Yahoo Finance Plus to view Fair Value for NVS
Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.
Novartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight key brands that are expected to have a multi-billion dollar peak sales potential.
Novartis AG on Thursday told investors that the Swiss drug maker plans to adopt a "U.S.-first mindset" in its bid to become a "top-five player" in the U.S. market by 2027. Novartis is one of the world's largest pharmaceutical companies; however in the U.S., it was the tenth largest by revenue in the U.S. in 2021,